Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillar...

Descripción completa

Detalles Bibliográficos
Autores principales: Puglisi, Fabio, Gerratana, Lorenzo, Lambertini, Matteo, Ceppi, Marcello, Boni, Luca, Montemurro, Filippo, Russo, Stefania, Bighin, Claudia, De Laurentiis, Michelino, Giuliano, Mario, Bisagni, Giancarlo, Durando, Antonio, Turletti, Anna, Garrone, Ornella, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Gravina, Adriano, De Placido, Sabino, Cognetti, Francesco, Del Mastro, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238951/
https://www.ncbi.nlm.nih.gov/pubmed/34183674
http://dx.doi.org/10.1038/s41523-021-00286-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238951/
https://www.ncbi.nlm.nih.gov/pubmed/34183674
http://dx.doi.org/10.1038/s41523-021-00286-w

Ejemplares similares